San Diego-based Kura Oncology, a clinical-stage biopharmaceutical company focused on precision cancer medicine, recently announced stock option grants to seven newly hired employees.
The grants, approved by the company’s Compensation Committee, were made under Kura‘s 2023 Inducement Option Plan. This action aligns with Nasdaq Listing Rule 5635(c)(4), which permits inducement awards to attract key personnel.
Each option allows the purchase of Kura common stock at an exercise price of $7.95 per share, reflecting the closing price on September 2, 2025, the date of the grant. The options vest gradually over a four-year period. A quarter of the shares vest after one year, with the remaining shares vesting monthly over the subsequent three years, contingent upon continued employment.
The terms and conditions of these grants are governed by Kura‘s 2023 Inducement Option Plan and individual stock option agreements. The company believes these grants are crucial in attracting and retaining talent to advance its research and development goals.
Kura Oncology is dedicated to developing precision medicines for cancer treatment. Its pipeline includes small molecule drug candidates targeting specific cancer signaling pathways, focusing on hematologic malignancies and solid tumors.
One of their key programs involves ziftomenib, a menin inhibitor aimed at treating certain acute myeloid leukemias. The company is also making strides in menin and farnesyl transferase inhibition to overcome resistance mechanisms in solid tumor therapies.
Greg Mann, Investor and Media Contact for Kura Oncology, is available for further inquiries. The company’s website provides additional information on its research and development activities.
Related
